Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company focused on products and services that prevent and treat disease in farm animals and pets. The ELAN news feed on Stock Titan aggregates company announcements, regulatory updates and other disclosures so readers can follow how Elanco’s strategy and product portfolio evolve over time.
Elanco regularly issues news on pet health innovations, including prescription products for dogs and cats. Recent press releases have covered developments in canine dermatology, such as Zenrelia tablets for control of itching and inflammation associated with skin allergies in dogs and Befrena, an injectable monoclonal antibody targeting canine allergic and atopic dermatitis. The company also reports on its Credelio and Credelio Quattro brands for parasite control in dogs and Credelio CAT for cats, including label expansions, emergency use authorizations and new indications such as protection related to Lyme disease and emerging tick species.
Investors and industry followers will also find farm animal and corporate updates, including quarterly financial results, guidance, restructuring plans and productivity initiatives like Elanco Ascend. News items describe trends in pet health and farm animal revenue, progress in innovation pipelines, changes to manufacturing and R&D footprints, and participation in major healthcare and investor conferences.
This ELAN news page helps readers track how Elanco’s innovation, portfolio and productivity strategy is reflected in product approvals, regulatory milestones, financial performance and strategic partnerships. For anyone monitoring animal health markets, veterinary therapeutics or ELAN stock, it provides a centralized view of the company’s most recent public communications.
TriRx Pharmaceutical Services announced an agreement to acquire two facilities from Elanco Animal Health, located in Shawnee, Kansas and Speke, United Kingdom. This acquisition includes physical assets and approximately 600 employees. The deal is set to enhance TriRx's manufacturing capacity and efficiency. A long-term supply agreement will maintain the production of existing Elanco products at these sites. The Shawnee facility is expected to close in the second half of 2021, while the Speke facility is anticipated to finalize by early 2022.
Summary not available.
Elanco Animal Health (NYSE: ELAN) is optimizing its manufacturing footprint post-acquisition of Bayer Animal Health by selling its Shawnee, Kansas and Speke, UK sites to TriRx Pharmaceuticals. This includes a long-term supply agreement and the transfer of ~600 employees. The sale is expected to incur impairment charges of $245M to $305M in Q2 2021, impacting EPS guidance by $0.43 to $0.54. Elanco anticipates a reduction in annual capital expenditures by $25M to $30M while expecting gross margins to reach 60% by 2023. Additionally, operations in Brazil will be consolidated to enhance efficiency.
Elanco Animal Health has appointed Marcela A. Kirberger as the new general counsel and corporate secretary, effective June 22. Kirberger brings over 20 years of corporate legal experience, previously serving at Roche Diagnostics and other major firms. Her role will encompass all of Elanco’s legal functions. The company's CEO, Jeff Simmons, highlighted her extensive background in regulated and pharma sectors as a valuable asset. Kirberger is also an advocate for Indiana's life sciences industry and aims to make a positive impact on animal health.
Kindred Biosciences (NASDAQ: KIN) announced positive results from a pivotal study of KIND-030 for treating canine parvovirus. The trial showed a 100% survival rate in dogs treated with KIND-030 compared to 43% in the placebo group. This monoclonal antibody targets canine parvovirus, offering a single injection treatment that eliminates the need for costly hospitalization. The results indicate potential for both treatment and prevention of the disease, with submissions for regulatory approval expected soon. Parvovirus has a mortality rate up to 91% if untreated, making this a critical advancement.
Elanco Animal Health Incorporated (NYSE: ELAN) has announced its participation in two upcoming investor conferences in June. Jeff Simmons, the president and CEO, will hold a fireside chat at the Stifel 2021 Virtual Jaws & Paws Conference on June 3 at 2:30 p.m. ET, lasting approximately 25 minutes. He will also present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10 at 9:40 a.m. ET for about 40 minutes. Both conferences will be virtual, with live webcasts accessible on Elanco's investor website.
Elanco Animal Health has launched ZoaShield™ in the U.S., a solution for poultry producers to manage coccidiosis effectively. This new product features a proven active ingredient, zoalene, which is vital for maintaining optimal bird health, especially in No Antibiotics Ever (NAE) flocks. Elanco emphasizes that ZoaShield offers producers flexibility to suit various operational needs and seasons. Additionally, the company provides consultative support from experienced field experts, enhancing operational efficiency for poultry producers.
Elanco Animal Health reported strong Q1 2021 results, achieving revenue of $1,242 million, a significant rise from previous guidance of $1,150 - $1,170 million. The addition of Bayer Animal Health contributed $559 million to revenue. Adjusted EPS was $0.37, exceeding expectations. Pet Health revenue surged 213%, while global Seresto sales declined by 9%. Operating expenses were lower than anticipated, enabling Elanco to raise its 2021 guidance for revenue and adjusted EBITDA. The company expects eight product launches to drive future revenue growth.
Elanco Animal Health has launched Credelio Cat, the first oral flea and tick control product for cats, approved by the FDA. This chewable treatment starts killing fleas within 6 hours and provides protection against black-legged ticks for a month. Designed for cats 8 weeks and older, Credelio Cat is palatable and has a high success rate in administration, with 99.5% of owners successfully giving it to their cats. The product joins Elanco's extensive pet health portfolio, addressing a significant market need for effective oral parasite prevention in cats.
On April 28, 2021, Kindred Biosciences (NASDAQ: KIN) announced that the USDA has accepted the efficacy data for its monoclonal antibody, KIND-030, aimed at preventing canine parvovirus (CPV) infection. The pivotal study showed that 0% of treated dogs developed CPV, while the placebo group had a 100% infection rate. This acceptance is a significant milestone, progressing KindredBio's drug development for pets. The company expects to complete the efficacy study for treating established CPV by mid-2021.